ICYMI, some of this week’s featured content includes new safety data on baricitinib for atopic dermatitis, low malignancy risk for secukinumab in psoriasis, new columns, video coverage from the Inaugural Symposium for Inflammatory Skin Disease, plus more.
Given the high prevalence of Kawasaki disease during the pandemic, Japanese investigators determined that droplet or contact transmission of pathogens is likely not a major route causing the development of the disease.
This week’s edition of The Mainstream Patient features stories on fraxel lasers, microcurrent facials, perioral dermatitis, brow lifts, plus more.
In this month's Cosmetic Conundrums column, Dermatology Times Chief Medical Editor Zoe Diana Draelos, MD, discusses how to solve common challenges associated with pierced earrings.
Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.
A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.
Data from trials show tazarotene 0.045% lotion is an effective treatment for moderate to severe facial acne and improves acne-related QOL in patients across BMI categories.
Some strains appear to reduce risk in pregnant women and infants
Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.
In this month's Legal Eagle column, David J. Goldberg, MD, JD, explores the legality of terminating an employee for refusing a COVID-19 vaccine.
In this video interview, Linda Stein Gold, MD, discusses her recent presentation at the Inaugural SISD regarding using topicals for atopic dermatitis.